Overview

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

Status:
Completed

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

This study was to assess the safety and efficacy of sofosbuvir in combination with ribavirin (RBV) administered for 12 or 16 weeks in participants with genotypes 2 or 3 hepatitis C virus (HCV) infection as assessed by the proportion of participants with sustained virologic response (SVR) 12 weeks after discontinuation of therapy (SVR12).

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Ribavirin
Sofosbuvir